Select therapeutic targets for validation
Which targets should I test to change a defined disease-relevant phenotype?
Evidence collection plan
Collection plannedEvidence collection is planned for this question. The plan defines a comparison to investigate; it does not establish model performance or suitability.
Comparison question
Does a proposed ranking identify more reproducible disease-relevant target effects than conventional evidence aggregation at the same validation budget?
Baselines to include
- Genetics-only and expression-only rankings
- Simple dependency ranking or conventional evidence aggregation
Outcomes to measure
- Confirmed useful target effects among all candidates tested
- Reproducibility, rescue and context/selectivity
- Failed experiments and uncertainty about modulation direction
Validation requirements
- Define the disease, candidate universe, intervention direction, phenotype and budget before comparing rankings.
- Freeze input evidence before validation outcomes and audit overlap between discovery and validation data.
- Include failed experiments and normal-cell controls; retain untested candidates as untested.
- Keep target association, dependency, tractability and clinical success separate.
Next collection task
Build a disease-specific inventory of validation campaigns, including failed targets, evidence dates and conventional ranking baselines.
Your decision and inputs
Select targets and modulation directions for a validation batch, with clear tests of the proposed disease mechanism.
- Who this is for
- Disease biologists; Translational discovery teams
- Context
- Research
- Inputs
- A defined disease, biological context and experimental phenotype
- A candidate gene set and feasible ways to inhibit or activate each target
- Dated genetic, expression and functional evidence, including conflicting findings
- A validation budget and relevant normal-cell or selectivity controls
- Expected output
- A shortlist of target–disease–intervention hypotheses with supporting evidence, uncertainties and proposed validation experiments.
- Biological setting
- Research planning for one disease and a prespecified experimental system. The intended comparison tests whether rankings improve the yield of useful target effects.
Outside this use case
- Untested targets cannot be treated as negative examples.
- Cellular dependency, target tractability and a therapeutic window require different evidence.
- A target association does not establish that modulating it will benefit patients.
What this establishes for clinical research
Research only. Target prioritisation does not establish treatment benefit or support patient-specific treatment decisions.
Which evaluations inform this question?
No model comparison has been collected for this question yet.
Relevant methods and studies may exist outside this collection.
What evidence is still missing?
- Comparisons need independent validation campaigns that report failures as well as successful targets.
- Matched-budget evidence for phenotype effects, rescue and selectivity has not yet been collected for this question.
- Human domain review remains unassigned.
Sources and review
Automated source review · 2026-09-28 · Codex
Automated review of the workflow definition, cited primary-source scope and collection plan. No model evaluation or applicability mapping was added. Human domain review remains unassigned.
- Rewire research use-case priorities: workflow definitions and evidence plans · Original source ↗
R1 — Therapeutic target validation
Release provenance and downloads
Release 2026-09-28-c7b5ac6d34f2
Use-case input digest a0dd27a5f430ec387d309fd6e8615083250873ce4cff5e882c6fb8458ef80e95
Download questions, collection plans and review metadata (JSON) · Verify release checksums
Question use-case-therapeutic-target-validation. Any numerical results on this page come from this release's existing evaluation records.